Licensing operations can also cause confusion by making transactions more difficult. “They are not generally counted as assets on the balance sheet,” Jeff Margolis, vice president of RespireRx (OTCQB:RSPI), told the news information network. More and more biotech and pharmaceutical companies are taking active steps to avoid (1) conflicts of cooperation and licensing; and (2) to resolve disputes that arise without resorting to litigation. There are a large number of non-procedural strategies that help companies cope with the uncertainties associated with cooperation and licensing agreements, including: licensing is also very attractive compared to pure M-A. This is because licenses allow pharmaceutical companies to acquire the rights to experimental drugs without taking back the baggage of another company, including unwanted technologies. THE REPORTING OBLIGATIONS OF VIEW AS OPPORTUNITIES Regular reporting obligations are a common feature in phased cooperation and licensing agreements. It is necessary for the licensee to inform the licensee, the seller and/or former shareholders of the development status of the licensed product and the efforts made so far to develop or market the product. These reports should receive much greater attention than a formality with language extracts and pasta from previous periods. On the contrary, regular reporting provides an invaluable and proactive opportunity to carefully and at the same time understand the licensee`s efforts in favour of certain milestones or other obligations within the framework of the agreement. It is also a way of documenting a company`s argument in a thorough and well-thought-out way if it decides to stop development. By keeping the licensee informed of development efforts, the licensee can manage expectations and hopefully avoid a costly battle of milestones. In the event of a dispute, these reports are essential evidence that the underwriter has demonstrated due diligence in the development of the agreement. In this agreement, Norgine is the licensee in, i.e.

it is licensed a product by AMAG; AMAG, which licenses its product to Norgine, is the out licensee. These agreements are popular because they allow a company (in this case Norgine) to cover part of the financial, regulatory or technological costs associated with the development of another company`s product (in this case AMAG). Both benefit at the end. 7) For a licensed development product, what is the first material to be prepared at the beginning of the licensing activity? Just as pharmaceutical companies are always looking for the next drug to blockbuster, investors are looking for the company that will develop it. For this reason, licensing agreements can be a bit repugnant – even if a drug is extremely effective, its benefits must be split between two pharmaceutical companies and therefore two groups of shareholders. A termsheet is usually (but not always) a written but unsigned summary of the proposed agreement, which can be used by lawyers to develop the effective agreement.


Related Posts